Skip Navigation


Rheumatology Advance Access originally published online on August 1, 2008
Rheumatology 2008 47(10):1590-1591; doi:10.1093/rheumatology/ken319
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
47/10/1590    most recent
ken319v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Search for Related Content
Related Collections
Right arrow Pharmacology
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Comment on: Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance: Editor's note

Editor

Rheumatology

Correspondence to: The Editor, British Society for Rheumatology, Bride House, 18-20 Bride Lane, London EC4Y 8EE, UK. E-mail: editorial{at}rheumatology.org.uk

The editorial office has investigated the allegations made by Dr Kobelt in their letter [1] regarding undeclared conflicts of interest in an article by Dr Wailoo and co-authors [2]. The editorial office is satisfied that Dr Wailoo and co-authors have complied with Rheumatology's requirements for the declaration of interests relevant to their article.


   References
Top
 References
 

  1. Kobelt G. Comment on: Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance. Rheumatology (2008) 47:1589–90.[Free Full Text]
  2. Wailoo A, Bansback N, Chilcott J. Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance. Rheumatology (2008) 47:119–20.[Free Full Text]
Accepted 7 July 2008


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
47/10/1590    most recent
ken319v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Search for Related Content
Related Collections
Right arrow Pharmacology
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?